736 related articles for article (PubMed ID: 29644751)
1. Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations.
Lang AE; Espay AJ
Mov Disord; 2018 May; 33(5):660-677. PubMed ID: 29644751
[TBL] [Abstract][Full Text] [Related]
2. Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic.
Sardi SP; Cedarbaum JM; Brundin P
Mov Disord; 2018 May; 33(5):684-696. PubMed ID: 29704272
[TBL] [Abstract][Full Text] [Related]
3. Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
Oertel W; Schulz JB
J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098
[TBL] [Abstract][Full Text] [Related]
4. Disease-modifying strategies for Parkinson's disease.
Kalia LV; Kalia SK; Lang AE
Mov Disord; 2015 Sep; 30(11):1442-50. PubMed ID: 26208210
[TBL] [Abstract][Full Text] [Related]
5. New Frontiers in Parkinson's Disease: From Genetics to the Clinic.
Shihabuddin LS; Brundin P; Greenamyre JT; Stephenson D; Sardi SP
J Neurosci; 2018 Oct; 38(44):9375-9382. PubMed ID: 30381429
[TBL] [Abstract][Full Text] [Related]
6. Approaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned.
Hung AY; Schwarzschild MA
Neurotherapeutics; 2020 Oct; 17(4):1393-1405. PubMed ID: 33205384
[TBL] [Abstract][Full Text] [Related]
7. Autosomal dominant Parkinson's disease and the route to new therapies.
Morris HR
Expert Rev Neurother; 2007 Jun; 7(6):649-56. PubMed ID: 17563248
[TBL] [Abstract][Full Text] [Related]
8. Parkinson's disease: etiopathogenesis and treatment.
Jankovic J; Tan EK
J Neurol Neurosurg Psychiatry; 2020 Aug; 91(8):795-808. PubMed ID: 32576618
[TBL] [Abstract][Full Text] [Related]
9. Alpha-synuclein and iron: two keys unlocking Parkinson's disease.
Lingor P; Carboni E; Koch JC
J Neural Transm (Vienna); 2017 Aug; 124(8):973-981. PubMed ID: 28168622
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers of Parkinson's disease: present and future.
Miller DB; O'Callaghan JP
Metabolism; 2015 Mar; 64(3 Suppl 1):S40-6. PubMed ID: 25510818
[TBL] [Abstract][Full Text] [Related]
11. Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.
Espay AJ; Schwarzschild MA; Tanner CM; Fernandez HH; Simon DK; Leverenz JB; Merola A; Chen-Plotkin A; Brundin P; Kauffman MA; Erro R; Kieburtz K; Woo D; Macklin EA; Standaert DG; Lang AE
Mov Disord; 2017 Mar; 32(3):319-324. PubMed ID: 28233927
[TBL] [Abstract][Full Text] [Related]
12. The evidence for disease modification in Parkinson's disease.
Lew MF
Int J Neurosci; 2011; 121 Suppl 2():18-26. PubMed ID: 22035026
[TBL] [Abstract][Full Text] [Related]
13. Can the disease course in Parkinson's disease be slowed?
Korczyn AD; Hassin-Baer S
BMC Med; 2015 Dec; 13():295. PubMed ID: 26653056
[TBL] [Abstract][Full Text] [Related]
14. Targeting α-Synuclein in Parkinson's Disease: Progress Towards the Development of Disease-Modifying Therapeutics.
Savitt D; Jankovic J
Drugs; 2019 Jun; 79(8):797-810. PubMed ID: 30982161
[TBL] [Abstract][Full Text] [Related]
15. Parkinson Diseases in the 2020s and Beyond: Replacing Clinico-Pathologic Convergence With Systems Biology Divergence.
Espay AJ; Lang AE
J Parkinsons Dis; 2018; 8(s1):S59-S64. PubMed ID: 30584155
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Parkinson's disease : what's on the horizon?
Wu SS; Frucht SJ
CNS Drugs; 2005; 19(9):723-43. PubMed ID: 16142989
[TBL] [Abstract][Full Text] [Related]
17. Investigational α-synuclein aggregation inhibitors: hope for Parkinson's disease.
Török N; Majláth Z; Szalárdy L; Vécsei L
Expert Opin Investig Drugs; 2016 Nov; 25(11):1281-1294. PubMed ID: 27677932
[TBL] [Abstract][Full Text] [Related]
18. Progress of Pharmacological Approaches in Parkinson's Disease.
Zeuner KE; Schäffer E; Hopfner F; Brüggemann N; Berg D
Clin Pharmacol Ther; 2019 May; 105(5):1106-1120. PubMed ID: 30661251
[TBL] [Abstract][Full Text] [Related]
19. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
[TBL] [Abstract][Full Text] [Related]
20. New hopes for disease modification in Parkinson's Disease.
Poewe W; Seppi K; Marini K; Mahlknecht P
Neuropharmacology; 2020 Jul; 171():108085. PubMed ID: 32298705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
